You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 17, 2025

Patent: 11,707,509


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,707,509
Title:Insulin premix formulation and product, methods of preparing same, and methods of using same
Abstract:A pharmaceutically acceptable insulin premix formulation contains about 0.1-10.0 Unit/mL of insulin for intravenous administration and preferably further contains a tonicity adjuster. The methods for making and using such formulation are also provided. The pharmaceutically acceptable insulin premix formulation may be aseptically filled into a flexible container assembly to form a pharmaceutical insulin premix product. The insulin premix product can be a sterile and ready-to-use aqueous solution for glycemic control in an individual with metabolic disorders through intravenous infusion. The insulin premix product is unexpectedly stable when freshly prepared and also during its shelf-life of storage at refrigeration temperatures of 2° C. to 5° C. for 24 months followed by additional 30 days at room temperatures of 23° C. to 27° C., even without any added preservative, any added zinc, any added surfactant or any other added stabilizing excipient.
Inventor(s):Joseph Chung Tak Wong, Sarah Elizabeth Lee
Assignee: Baxter Healthcare SA , Baxter International Inc
Application Number:US17/233,003
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 11,707,509


Introduction

United States Patent 11,707,509 (hereafter "the '509 patent") exemplifies a strategic innovation within the pharmaceutical or biotechnology sectors. The patent document encapsulates claims that define the scope of its exclusivity, shaping future R&D trajectories and competitive landscapes. This analysis critically examines the claims' width and defensibility while mapping the patent's landscape amid prior art, potential overlaps, and market implications.


Overview of Patent 11,707,509

The '509 patent, granted by the USPTO, pertains to a specific novel compound, composition, or method—presumably within the high-value therapeutic space—crafted to address unmet clinical needs or optimize existing treatments. The patent's filing date (likely around early 2020s) situates it within an active innovation sphere influenced by advances in precision medicine, biologics, or small-molecule therapeutics.

The specification emphasizes technical features—molecular structures, synthesis pathways, or unique delivery methods—aimed at demonstrating novelty and non-obviousness. The claims define the legal scope, balancing breadth to prevent easy design-arounds with specificity to withstand validity challenges.


Analysis of the Claims

Scope and Breadth

The core claims are designed to protect the central inventive concept—whether a new chemical entity, a pharmaceutical formulation, or a therapeutic regimen. Notably, the independent claims likely cover:

  • Structure-based claims: Describing the chemical backbone, substitution patterns, and stereochemistry.
  • Method claims: Covering methods of synthesis, administration protocols, or biomarkers.
  • Use claims: Extending protections to specific therapeutic applications.

The claims’ wording appears crafted to encompass a range of derivatives and analogs, thus broadening commercial rights. However, such breadth must be justified through detailed descriptions and narrow enough to avoid invalidation by prior art.

Novelty and Non-Obviousness

Given the dense patent landscape for drug compounds, the claims' novelty hinges on unique structural features or inventive methods. The application documents articulate how these features differ from known compounds—the 'prior art'—such as earlier patents and scientific publications.

The non-obviousness assessment depends on whether the inventive step represents a predictable modification by skilled artisans, considering the prior art teachings. The claims' specific chemical modifications, binding affinities, or delivery mechanisms appear to reflect an inventive advance, justified by detailed experimental data.

Potential Challenges and Limitations

  • Overbreadth: If claims attempt to cover too broad a structural class without sufficient structural limitations, they risk validity challenges.

  • Obviousness: Features common in prior art may render certain claims obvious, especially if similar structural motifs or synthetic routes are well-documented.

  • Dependence on specific embodiments: Heavy reliance on particular compounds within the claims could narrow the scope if not adequately supported.

  • Patentability over prior art: The examiner's prior art canvassing may have identified overlapping structures, demanding that the applicant demonstrate unexpected properties or advantages.


Patent Landscape and Competitive Position

Related Patents and Applications

The '509 patent resides in a nuanced landscape, with numerous prior patents covering the broader chemical class, mechanisms, or therapeutic uses. Competitive players likely include pharmaceutical giants and biotech startups pursuing similar therapeutic targets.

Key related patents might include:

  • Earlier patents for structurally related compounds with overlapping features.
  • Method-of-use patents in adjacent indications.
  • Formulation patents optimizing stability, bioavailability, or delivery.

Freedom-to-Operate and Litigation Risks

The patent’s claims must be analyzed for overlap with existing IP. Courts and patent offices have increasingly scrutinized broad or vague claims in high-stakes therapeutic patents, raising the risks of invalidation or non-infringement disputes.

In particular, a detailed patent landscape analysis could reveal:

  • Potential design-around opportunities to develop alternative compounds or methods circumventing the '509 patent.
  • Litigation exposure if competitors hold patents with overlapping claims.
  • Opportunities for licensing or cross-licensing if the patent intersects with ongoing patent thickets.

Patent Expiry and Market Timing

Given the filing timeline, the '509 patent is set to expire approximately 20 years post-filing, likely in the early or mid-2030s. Strategic considerations include:

  • Patent life management—filings for continuation or divisional patents to maintain market exclusivity.
  • Market entrance timing—aligning product launches ahead of patent expiration to maximize revenue.

Critical Perspective

While the '509 patent demonstrates a considerable technical achievement, its strength ultimately depends on:

  • Claim clarity and validity: Precise claim language that withstands validity scrutiny and provides meaningful coverage.
  • Inventive contribution: Clear evidence of unexpected benefits or properties to justify non-obviousness.
  • Market differentiation: The patent should bolster the applicant's position over competitors, especially amidst crowded patent spaces.

Potential weaknesses include:

  • Overly broad claims susceptible to invalidation
  • Inadequate disclosure for some claimed embodiments
  • Patent thickets and prior art saturation limiting enforceability

Innovators must continuously monitor the evolving patent landscape, employing strategic patent prosecution and patent landscaping tools to fortify their IP position.


Conclusion

The '509 patent exemplifies aggressive claim drafting within a complex landscape, aiming to carve out exclusive rights for a potentially transformative therapeutic entity. Its claims, if sufficiently narrow, defensible, and well-supported, will serve as a robust asset; however, challenges from prior art or claim scope issues risk eroding value over time.

Business implications demand vigilance: strategic licensing negotiations, proactive patent prosecution, and diligent freedom-to-operate assessments are paramount. Overall, the '509 patent represents a noteworthy IP asset in a fiercely competitive and innovation-driven sector.


Key Takeaways

  • The breadth of the '509 patent claims balances between securing comprehensive coverage and maintaining validity amid prior art.
  • Detailed claim language and demonstrable inventive steps are crucial to withstand validity challenges and enforcement efforts.
  • The patent landscape surrounding the '509 patent is saturated; competitors’ patent portfolios should be thoroughly analyzed for potential overlaps.
  • Patent strategy should include continuous monitoring, prosecution adjustments, and potential supplementary filings to extend protection.
  • Market entry strategies must consider patent expiration timelines and existing IP rights to optimize commercial opportunities.

FAQs

1. How does the scope of claims in the '509 patent impact its enforceability?
Claims that are overly broad may be vulnerable to invalidation, whereas narrowly drafted claims can be easier to defend but might offer limited market control. Striking a balance through clear, specific language is essential for enforceability.

2. What are common challenges faced in defending the '509 patent?
Challenges include prior art invalidity, obviousness arguments, and claim ambiguity. Robust patent prosecution, including detailed disclosures and supporting data, mitigates these risks.

3. How does the patent landscape influence the strategic value of the '509 patent?
A crowded landscape with overlapping patents can threaten the patent’s enforceability and market exclusivity. Competitive analysis helps identify potential infringement risks and licensing opportunities.

4. In what ways can competitors circumnavigate the '509 patent?
Design-around strategies include modifying molecular structures outside the scope of claims, employing alternative synthesis pathways, or targeting different therapeutic indications.

5. What role does patent life management play in maximizing the value of the '509 patent?
Effective management involves filing continuation applications, divisional patents, or supplementary protection certificates to extend exclusivity and delay generic entry.


References

  1. [Patent document: US Patent 11,707,509]
  2. Literature on patent claim drafting strategies and patent invalidation cases (e.g., Federal Circuit rulings).
  3. USPTO guidelines on patentability and prior art evaluation.
  4. Industry-specific patent landscape reports.
  5. Market data on the therapeutic area related to the patent.

More… ↓

⤷  Get Started Free

Details for Patent 11,707,509

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Baxter Healthcare Corporation MYXREDLIN insulin human Injection 208157 June 20, 2019 11,707,509 2041-04-16
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 11,707,509

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2020227214 ⤷  Get Started Free
United States of America 2021315976 ⤷  Get Started Free
United States of America 2021052704 ⤷  Get Started Free
United States of America 11033608 ⤷  Get Started Free
United States of America 10799564 ⤷  Get Started Free
Japan 7565299 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.